Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 20Thoracic 4Genitourinary 3Gastrointestinal 3Breast 3Sarcoma 1Other solid neoplasm 1Head & Neck 1

Conditions

Prostatic Neoplasms 334Carcinoma, Renal Cell 112Urinary Bladder Neoplasms 95Breast Neoplasms 55Carcinoma, Transitional Cell 52Colorectal Neoplasms 43Carcinoma, Non-Small-Cell Lung 42Melanoma 41Ovarian Neoplasms 39Kidney Neoplasms 39Neoplasms 38Neoplasm Metastasis 31Lung Neoplasms 28Sarcoma 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Pancreatic Neoplasms 24Endometrial Neoplasms 23Stomach Neoplasms 22Wilms Tumor 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Hepatocellular 19Esophageal Neoplasms 18Adenocarcinoma 18Triple Negative Breast Neoplasms 17Head and Neck Neoplasms 17Small Cell Lung Carcinoma 15Thyroid Neoplasms 14Metastatic Castration-resistant Prostate Cancer 14Neuroblastoma 13

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Genitourinary × 30 days × Clear all
NCT07334119 2026-05-20

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Myeloid Therapeutics

Phase 1 Recruiting
60 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04902872 2026-05-12

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Cybrexa Therapeutics

Phase 1/2 Completed
69 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Appendiceal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT04152499 2026-05-11

MK-2870-001

Klus Pharma Inc.

Phase 1/2 Active not recruiting
1,410 enrolled
BreastGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡